Pliant Therapeutics Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
114
- Stock Symbol
-
PLRX
- Share Price
-
$17.78
- (As of Thursday Closing)
Pliant Therapeutics General Information
Description
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 260 Littlefield Avenue
- San Francisco, CA 94080
- United States
+1 (650) 000-0000
Pliant Therapeutics Timeline
Pliant Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.78 | $18.38 | $3.96 - $26.25 | $896M | 48.8M | 449K | -$2.90 |
Pliant Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 869,689 | 265,482 | 512,102 | |
| Revenue | 9,719 | 7,572 | 41,817 | 57,052 |
| EBITDA | (112,613) | (96,000) | (40,335) | (118) |
| Net Income | (112,792) | (97,263) | (41,533) | (631) |
| Total Assets | 377,181 | 221,215 | 295,526 | 119,064 |
| Total Debt | 16,675 | 7,194 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Pliant Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pliant Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Pliant Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therap
Biotechnology
San Francisco, CA
114
As of 2022
00000
00000000
00000
00000
or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Watertown, MA
00
As of 0000
000.00
000000 - 000
000.00
000000
nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Norcross, GA
00
As of 0000
000000000000
Add Comparison
Pliant Therapeutics Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eloxx Pharmaceuticals | Formerly VC-backed | Watertown, MA | 00 | 000.00 | 000000 - 000 | 000.00 |
| 00000000 000000000 | Corporation | Norcross, GA | 00 | 000000000000 | ||
| 000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Brisbane, CA | 000 | 00000 | 000000000 | 00000 |
| 000000000 (0000000 | Formerly VC-backed | Mechelen, Belgium | 0000 | 00.000 | 000000000 | 00.000 |
Pliant Therapeutics Patents
Pliant Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220177468-A1 | Integrin inhibitor and uses thereof | Pending | 19-Nov-2020 | 0000000000 | |
| AU-2021268889-A1 | Treatment of respiratory diseases with amino acid compounds | Pending | 07-May-2020 | ||
| AU-2020408067-A1 | Combination treatment of liver diseases using integrin inhibitors | Pending | 20-Dec-2019 | 00000000000 | |
| CA-3164941-A1 | Combination treatment of liver diseases using integrin inhibitors | Pending | 20-Dec-2019 | 00000000000 | |
| AU-2020405182-A1 | Combination treatment of liver diseases using integrin inhibitors | Pending | 20-Dec-2019 | A61K31/4375 |
Pliant Therapeutics Executive Team (15)
Pliant Therapeutics Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bernard Coulie MD | Pliant Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| David Pyott | Self | Board Member | 000 0000 |
| Gayle Crowell | Self | Board Member | 000 0000 |
| Hoyoung Huh Ph.D | Self | Board Member | 000 0000 |
| John Curnutte MD | Self | Board Member | 000 0000 |
Pliant Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Pliant Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|